文献速递前列腺癌

磁共振成像路径检测前列腺癌准确性的系统评价与荟萃分析

Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-14

该系统评价与荟萃分析纳入15项研究,评估MRI路径(MRI引导活检)对临床显著前列腺癌(Gleason≥7)的检测灵敏度。汇总灵敏度为78.3%(95%CI 75.0-81.4%),研究间异质性中等(I2=36%)。结论认为MRI路径尚不能单独用于诊断临床显著疾病,活检时仍应进行系统采样。

要点

  • MRI路径检测临床显著前列腺癌的汇总灵敏度为78.3%。
  • 纳入研究质量偏低,盲法不充分可能引入偏倚。
  • MRI路径尚不能替代系统活检,活检时应同时进行系统采样。

核心结论

  • MRI路径尚不能单独依赖来诊断临床显著前列腺癌,活检过程中仍应进行额外的系统采样。

研究设计与样本

  • 系统评价与荟萃分析,检索多个数据库至2017年5月,纳入15项评估MRI引导活检准确性的研究。
  • 参考标准为同时进行MRI引导活检和至少20针的系统活检。

主要发现

  • MRI路径检测临床显著前列腺癌(Gleason≥7)的汇总灵敏度为78.3%(95%CI 75.0-81.4%)。
  • 纳入研究间存在中等异质性(I2=36%)。
  • 按临床场景、MRI磁场强度和图像融合模式进行亚组分析,未发现亚组间交互作用。
  • 未发现发表偏倚。

关键数值与推荐

  • 临床显著前列腺癌定义为Gleason≥7疾病。
  • 参考标准要求系统活检至少20针。

临床怎么用

  • 在活检过程中,不应仅依赖MRI路径,应同时进行系统采样以提高临床显著前列腺癌的检出。

局限性

  • 纳入研究总体质量偏低,人员盲法不充分,可能引入性能偏倚和检测偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although magnetic resonance imaging and subsequent targeted biopsy ('MRI pathway') have been widely adopted in routine clinical practice, it is still a common practice to perform systematic biopsy concurrently, because the accuracy of the MRI pathway is yet to be fully defined. This systematic review of the literature assessed the sensitivity of the MRI pathway for detecting clinically significant prostate cancer. METHODS: Multiple databases were searched up to May 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement for studies assessing the accuracy of MR-guided biopsy (MRGB) compared to a reference standard which consisted of both MRGB and systematic biopsy with at least 20-cores. The primary outcome was the sensitivity of detecting clinically significant prostate cancer defined as Gleason ≥7 disease. RESULTS: A total of 15 studies met the predefined inclusion criteria. Overall, studies were assessed to be of low quality with inadequate blinding of personnel, which could introduce performance and detection bias. The calculated summary sensitivity of the MRI pathway was 78.3% [95%CI 75.0-81.4%]. There was moderate heterogeneity between the included studies (I2 = 36%). Subgroup analysis was performed based on clinical setting, the strength of MRI magnet and mode of image fusion as factors but no interaction was identified between any of the subgroups. No publication bias was identified. CONCLUSION: The MRI pathway cannot yet be solely relied upon to diagnose clinically significant disease and hence additional systematic sampling should still be performed during the biopsy procedure.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sathianathen NJ, Butaney M, Bongiorno C, et al. Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018. PMID: 30108376. doi:10.1038/s41391-018-0075-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。